Cargando…

The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis

We sought to analyze the efficacy of adalimumab in active noninfectious uveitis, and evaluate its efficacy and safety for the management of refractory noninfectious uveitis in Korean patients. A retrospective observational study was conducted. A total of 23 eyes of 14 Korean patients with noninfecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Sung Eun, Jun, Jae Won, Lee, Dong Hyun, Lee, Sung Chul, Kim, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Yonsei University College of Medicine 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859681/
https://www.ncbi.nlm.nih.gov/pubmed/33527798
http://dx.doi.org/10.3349/ymj.2021.62.2.177
_version_ 1783646787046735872
author Park, Sung Eun
Jun, Jae Won
Lee, Dong Hyun
Lee, Sung Chul
Kim, Min
author_facet Park, Sung Eun
Jun, Jae Won
Lee, Dong Hyun
Lee, Sung Chul
Kim, Min
author_sort Park, Sung Eun
collection PubMed
description We sought to analyze the efficacy of adalimumab in active noninfectious uveitis, and evaluate its efficacy and safety for the management of refractory noninfectious uveitis in Korean patients. A retrospective observational study was conducted. A total of 23 eyes of 14 Korean patients with noninfectious uveitis refractory to conventional treatment, including corticosteroid and immunosuppressive agents, were treated with adalimumab between December 2017 and February 2020. The primary outcomes were vitreous haziness grades, anterior chamber cell grades, and central macular thickness measured prior to injection and at 1, 3, 6, and 12 months after the first adalimumab injection. Among the 23 eyes, 14 eyes (60.9%) were diagnosed with panuveitis and 9 eyes (39.1%) with posterior uveitis [mean follow-up period: 22.3 months (7–27)]. The most common etiologic diagnoses requiring adalimumab injection were Behçet's disease (9 eyes, 39.1%), followed by undifferentiated inflammation (6 eyes, 26.1%), Vogt-Koyanagi-Harada disease (3 eyes, 13.0%), psoriasis (2 eyes, 8.7%), serpiginous chorioretinopathy (2 eyes, 8.7%), and systemic lupus erythematosus (1 eye, 4.3%). At the 1-year follow-up after the first injection, anterior chamber cell grade decreased from 0.5±0.4 to 0.3±0.4, and vitreous haziness grade decreased from 1.1±1.1 to 0.3±0.5 (p<0.05). Central macular thickness improved from 347.2±98.1 µm to 264.3±61.1 µm (p<0.05). Adalimumab injection in patients with refractory noninfectious uveitis decreased the anterior chamber cell grade, vitreous haziness grade, and central macular thickness with no severe side effect. Overall, adalimumab injection may, therefore, be an effective and relatively safe treatment modality for noninfectious uveitis in Korean patients.
format Online
Article
Text
id pubmed-7859681
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Yonsei University College of Medicine
record_format MEDLINE/PubMed
spelling pubmed-78596812021-02-11 The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis Park, Sung Eun Jun, Jae Won Lee, Dong Hyun Lee, Sung Chul Kim, Min Yonsei Med J Brief Communication We sought to analyze the efficacy of adalimumab in active noninfectious uveitis, and evaluate its efficacy and safety for the management of refractory noninfectious uveitis in Korean patients. A retrospective observational study was conducted. A total of 23 eyes of 14 Korean patients with noninfectious uveitis refractory to conventional treatment, including corticosteroid and immunosuppressive agents, were treated with adalimumab between December 2017 and February 2020. The primary outcomes were vitreous haziness grades, anterior chamber cell grades, and central macular thickness measured prior to injection and at 1, 3, 6, and 12 months after the first adalimumab injection. Among the 23 eyes, 14 eyes (60.9%) were diagnosed with panuveitis and 9 eyes (39.1%) with posterior uveitis [mean follow-up period: 22.3 months (7–27)]. The most common etiologic diagnoses requiring adalimumab injection were Behçet's disease (9 eyes, 39.1%), followed by undifferentiated inflammation (6 eyes, 26.1%), Vogt-Koyanagi-Harada disease (3 eyes, 13.0%), psoriasis (2 eyes, 8.7%), serpiginous chorioretinopathy (2 eyes, 8.7%), and systemic lupus erythematosus (1 eye, 4.3%). At the 1-year follow-up after the first injection, anterior chamber cell grade decreased from 0.5±0.4 to 0.3±0.4, and vitreous haziness grade decreased from 1.1±1.1 to 0.3±0.5 (p<0.05). Central macular thickness improved from 347.2±98.1 µm to 264.3±61.1 µm (p<0.05). Adalimumab injection in patients with refractory noninfectious uveitis decreased the anterior chamber cell grade, vitreous haziness grade, and central macular thickness with no severe side effect. Overall, adalimumab injection may, therefore, be an effective and relatively safe treatment modality for noninfectious uveitis in Korean patients. Yonsei University College of Medicine 2021-02-01 2021-01-25 /pmc/articles/PMC7859681/ /pubmed/33527798 http://dx.doi.org/10.3349/ymj.2021.62.2.177 Text en © Copyright: Yonsei University College of Medicine 2021 https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Brief Communication
Park, Sung Eun
Jun, Jae Won
Lee, Dong Hyun
Lee, Sung Chul
Kim, Min
The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
title The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
title_full The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
title_fullStr The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
title_full_unstemmed The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
title_short The Effect of Adalimumab in Korean Patients with Refractory Noninfectious Uveitis
title_sort effect of adalimumab in korean patients with refractory noninfectious uveitis
topic Brief Communication
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7859681/
https://www.ncbi.nlm.nih.gov/pubmed/33527798
http://dx.doi.org/10.3349/ymj.2021.62.2.177
work_keys_str_mv AT parksungeun theeffectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis
AT junjaewon theeffectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis
AT leedonghyun theeffectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis
AT leesungchul theeffectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis
AT kimmin theeffectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis
AT parksungeun effectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis
AT junjaewon effectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis
AT leedonghyun effectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis
AT leesungchul effectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis
AT kimmin effectofadalimumabinkoreanpatientswithrefractorynoninfectiousuveitis